MYOV - Myovant Reports Data And Other News: The Good Bad And Ugly Of Biopharma
- Myovant reports additional data from uterine fibroids study.
- Fortress Biotech reports start of AL Amyloidosis Phase 3 studies.
- Avita begins enrolment for vitiligo repigmentation pivotal study.
For further details see:
Myovant Reports Data, And Other News: The Good, Bad And Ugly Of Biopharma